Przedborski S, Levivier M, Cadet J L
Laboratory of Preclinical Neurosciences, College of Physicians and Surgeons, Columbia University, New York, NY 10032.
Ann Neurol. 1991 Nov;30(5):650-4. doi: 10.1002/ana.410300504.
We have investigated the presence of neurotensin receptors in human meningiomas by in vitro binding autoradiography. Ten of the 12 meningiomas tested displayed specific [3H]neurotensin binding. All meningothelial (n = 3) and transitional (n = 5) meningiomas were positive, whereas only 2 of the 4 fibroblastic meningiomas showed measurable concentrations of neurotensin binding sites. Within the tumors, [3H]neurotensin binding was preferentially observed in syncytial areas. Saturation experiments showed that the maximal binding capacity (Bmax) greatly varied among tumors, ranging from low values to more than 290 fmol/mg of protein. All positive tumors had neurotensin binding sites with a dissociation constant (kd) within the nanomolar range and a pharmacological specificity for [3H]neurotensin similar to neurotensin receptors.
我们通过体外放射自显影术研究了人类脑膜瘤中神经降压素受体的存在情况。在检测的12例脑膜瘤中，有10例显示出特异性的[3H]神经降压素结合。所有的脑膜内皮型（n = 3）和过渡型（n = 5）脑膜瘤均为阳性，而4例纤维母细胞型脑膜瘤中只有2例显示出可测量的神经降压素结合位点浓度。在肿瘤内部，[3H]神经降压素结合优先出现在合体细胞区域。饱和实验表明，最大结合容量（Bmax）在不同肿瘤之间差异很大，范围从低值到超过290 fmol/mg蛋白质。所有阳性肿瘤的神经降压素结合位点的解离常数（kd）在纳摩尔范围内，并且对[3H]神经降压素具有与神经降压素受体相似的药理学特异性。
